Targeting Novo Nordisk in China's obesity market with a unique proposition, LeaderMed eyes US IPO

The strained Sino-American relationship and China’s harsh drug price cuts have dampened interest in biotechs with Chinese ties. But Sanofi veteran Joanne Jiang, Ph.D., still hopes her new company, with a unique business proposition to tackle China’s metabolic disease market, will attract U.S. investors in a New York IPO planned for June 2024.